NEXT Life Sciences Advances Two Non-Hormonal Male Contraceptives Into Phase II Clinical Trials
Key Insights
NEXT Life Sciences (search) has advanced two non-hormonal male contraceptive options, Plan A™ (search) and NLS-133 (search), into Phase II clinical trials, marking significant progress in expanding male birth control options beyond condoms and vasectomy.
Plan A™ (search) demonstrated 100% delivery device success in early trials across Australia and Canada, while NLS-133 (search) offers a 24-hour protection pill designed for on-demand or daily use.
The development addresses a critical unmet need, with over 17 million American men actively seeking new contraceptive options and research showing 70% of men willing to try new male contraceptive methods.
NEXT Life Sciences (search) has achieved a significant milestone in reproductive health by advancing two non-hormonal male contraceptive options into Phase II clinical trials, potentially addressing a decades-long gap in male birth control options. The company's flagship product Plan A™ (search) and its on-demand pill NLS-133 (search) represent the first comprehensive platform for male contraception to reach this advanced stage of clinical development.
Plan A™ Demonstrates Early Success
Plan A™ (search), described as a long-acting, non-hormonal, and reversible-on-demand contraceptive option, achieved 100% delivery device success in early trials conducted in Australia and Canada during 2025. The contraceptive system entered Phase II clinical trials in October 2025, marking a crucial advancement for the flagship product.
"We are thrilled to have two male contraceptives now in clinical trials with promising preliminary results," said Darlene Walley, PhD, Chief Executive Officer of NEXT Life Sciences (search). "With a broader pipeline of reproductive and sexual health products in development, NEXT Life Sciences is stepping forward as the leader in non-hormonal, reversible-on-demand contraceptive options."
NLS-133 Offers On-Demand Protection
The company's second contraceptive candidate, NLS-133 (search), represents a different approach to male birth control. This non-hormonal male contraceptive pill is designed to provide 24 hours of protection and can be used either as an on-demand or daily pill. The Phase II clinical trial for NLS-133 is currently evaluating participants' semen levels after taking the contraceptive pill to demonstrate its effectiveness.
Bob Dudley, PhD, Chief Technology Officer at NEXT Life Sciences (search), explained the significance of these developments: "As a leader in male contraceptives, NEXT Life Sciences is bringing exciting new opportunities to market so men and their partners can have more choices than just condoms and vasectomies. Our transformative reproductive and sexual health products will revolutionize an area of healthcare that has had very little investment and innovation, finally bringing solutions to this unmet need."
Addressing Critical Unmet Medical Need
The development of these contraceptives addresses a substantial gap in reproductive healthcare. Currently, half of pregnancies worldwide remain unplanned, highlighting the disconnect between available contraceptive options and actual family planning needs. The burden of contraception continues to fall almost entirely on women, with recent data showing that 50% of women experience side effects from birth control that are more severe than expected.
The medical necessity for alternative options is further underscored by the fact that over 20% of women cannot tolerate hormonal birth control, sometimes with severe consequences. This creates a compelling case for non-hormonal alternatives that can shift some contraceptive responsibility to male partners.
Market Demand and Clinical Readiness
Research published in Andrology indicates that 7 in 10 men are willing to try new male contraceptive methods, signaling significant readiness for broader participation in family planning. Despite this willingness, male contraceptive options remain limited to condoms or vasectomy, leaving substantial demand unmet.
The scale of this unmet need is considerable, with over 17 million American men actively seeking new contraceptive options. This demand, combined with couples asking for more shared responsibility in family planning, creates a substantial market opportunity for effective male contraceptive solutions.
Clinical Development and Future Plans
Both contraceptives are positioned as non-hormonal solutions, addressing concerns about hormonal side effects that have historically limited male contraceptive development. The Phase II trials represent a critical step in demonstrating both safety and efficacy for these novel approaches to male birth control.
To support continued clinical development and expansion, NEXT Life Sciences (search) is planning a Series A funding round in 2026, following what the company describes as an oversubscribed Seed round. This funding strategy suggests confidence in the clinical prospects for both contraceptive candidates.
The advancement of Plan A™ (search) and NLS-133 (search) into Phase II trials represents a significant step forward in addressing what Walley characterized as a "long-unmet need" in contraceptive choice for men and couples worldwide. As the company continues to develop its broader pipeline of reproductive and sexual health products, these trials will provide crucial data on the viability of non-hormonal male contraception as a mainstream family planning option.